WELCOME
Norovirus
NOROVIRUS
Norovirus is the leading cause of infectious gastroenteritis in developed countries worldwide. Outbreaks of the virus are very common in long-term care facilities, hospitals and schools, and complications related to the infection can include organ dysfunction or even death. LigoCyte has developed a first-in-class VLP vaccine against norovirus that is currently undergoing human testing.
Read More
Influenza
respiratory viruses
LigoCyte is developing vaccines against two of the most common causes of respiratory viral infections, respiratory syncytial virus and influenza.  Both programs are based on the company’s proprietary virus-like particle technology, and each has achieved animal proof-of-principle against virus challenge in gold-standard models of infection.
Read More
Ligocyte Office
COMPANY
LigoCyte is a clinical-stage biologic drug development company focused on respiratory and gastrointestinal indications. The company’s virus-like particle (VLP) vaccine technologies support products that induce robust immune responses to prevent serious infections.
Read More
News Icon

DATA FROM LIGOCYTE’S CLINICAL STUDIES OF NOROVIRUS VLP VACCINE PRESENTED AT 13TH ANNUAL CONFERENCE ON VACCINE RESEARCH
Bethesda, Md., April 28, 2010.

LIGOCYTE PHARMACEUTICALS INITIATES A LIVE VIRUS CHALLENGE NOROVIRUS VACCINE STUDY
Tues, 08 Sept 2009, Source LigoCyte Pharmaceuticals, Inc.

Killer Outbreak: Nursing Home Residents in Hospital
ABC News, Australia  - Feb 12, 2009

Spike in Intestinal Virus Sets Off Alarm
The Denver Post, Denver, CO  - Feb 8, 2009

site by ///
"));